• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations.

作者信息

Tausch Eugen, Ljungström Viktor, Agathangelidis Andreas, Zapatka Marc, Scarfò Lydia, Jebaraj Billy Michael Chelliah, Yosifov Deyan Y, Müller Annika, Munugalavadla Veerendra, Degenhardt Jeremiah D, Ghia Paolo, Rosenquist Richard, Stilgenbauer Stephan

机构信息

Division of Chronic Lymphocytic Leukemia, Department of Internal Medicine III, Ulm University, Ulm, Germany.

Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.

出版信息

Blood. 2022 Jun 2;139(22):3340-3344. doi: 10.1182/blood.2021014550.

DOI:10.1182/blood.2021014550
PMID:35377939
Abstract
摘要

相似文献

1
Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations.idelalisib的继发性耐药的特征是IGF1R上调，而非MAPK/ERK途径突变。
Blood. 2022 Jun 2;139(22):3340-3344. doi: 10.1182/blood.2021014550.
2
PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.PI3Kδ抑制剂idelalisib联合BTK抑制剂ONO/GS-4059用于对PI3Kδ和BTK抑制剂获得性耐药的弥漫性大B细胞淋巴瘤
PLoS One. 2017 Feb 8;12(2):e0171221. doi: 10.1371/journal.pone.0171221. eCollection 2017.
3
Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma.idelalisib通过抑制套细胞淋巴瘤中的翻译调控机制影响细胞生长。
Clin Cancer Res. 2017 Jan 1;23(1):181-192. doi: 10.1158/1078-0432.CCR-15-3135. Epub 2016 Jun 24.
4
Anti-tumor activity of PI3K-δ inhibitor in hematologic malignant cells: Shedding new light on resistance to Idelalisib.PI3K-δ 抑制剂在血液恶性肿瘤细胞中的抗肿瘤活性：为伊德拉利昔布耐药性提供新的见解。
Int J Biochem Cell Biol. 2017 Apr;85:149-158. doi: 10.1016/j.biocel.2017.02.007. Epub 2017 Feb 22.
5
Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.骨髓基质诱导的慢性淋巴细胞白血病细胞对三氧化二砷的耐药性涉及Mcl-1上调，并且通过抑制PI3Kδ或PKCβ信号通路可克服这种耐药性。
Oncotarget. 2015 Dec 29;6(42):44832-48. doi: 10.18632/oncotarget.6265.
6
Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway.通过涉及 IGF1R 途径的多步机制对不可逆的表皮生长因子受体酪氨酸激酶抑制剂产生耐药性。
Cancer Res. 2013 Jan 15;73(2):834-43. doi: 10.1158/0008-5472.CAN-12-2066. Epub 2012 Nov 19.
7
Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients.伊德拉利昔单抗用于优化慢性淋巴细胞白血病患者的 CD19 特异性嵌合抗原受体 T 细胞。
Int J Cancer. 2019 Sep 1;145(5):1312-1324. doi: 10.1002/ijc.32201. Epub 2019 Feb 28.
8
Idelalisib.idelalisib（依地利斯布）
Recent Results Cancer Res. 2018;212:243-264. doi: 10.1007/978-3-319-91439-8_12.
9
The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression.PI3Kδ选择性抑制剂idelalisib诱导T细胞和NK细胞功能障碍，与B细胞恶性肿瘤相关的免疫抑制无关。
Front Immunol. 2021 Mar 15;12:608625. doi: 10.3389/fimmu.2021.608625. eCollection 2021.
10
Inhibitory effect of PI3Kδ inhibitor idelalisib on proliferation of human myeloid leukemia cells and the reversal effect on drug resistance to adriamycin.PI3Kδ 抑制剂idelalisib 对人髓系白血病细胞增殖的抑制作用及其对阿霉素耐药的逆转作用。
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2020 Dec 28;45(12):1389-1397. doi: 10.11817/j.issn.1672-7347.2020.190728.

引用本文的文献

1
Proteasome inhibition overcomes resistance to targeted therapies in B-cell malignancy models and in an index patient.蛋白酶体抑制克服了B细胞恶性肿瘤模型及一名索引患者对靶向治疗的耐药性。
Cell Death Dis. 2025 Jul 23;16(1):555. doi: 10.1038/s41419-025-07884-7.
2
B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia.慢性淋巴细胞白血病发病机制中的B细胞受体信号传导及相关通路
Front Oncol. 2024 Feb 26;14:1339620. doi: 10.3389/fonc.2024.1339620. eCollection 2024.
3
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.
PI3K/AKT/mTOR 信号转导通路与癌症的靶向治疗。
Mol Cancer. 2023 Aug 18;22(1):138. doi: 10.1186/s12943-023-01827-6.
4
Functional impact and molecular binding modes of drugs that target the PI3K isoform p110δ.针对 PI3K 同工型 p110δ 的药物的功能影响和分子结合模式。
Commun Biol. 2023 Jun 5;6(1):603. doi: 10.1038/s42003-023-04921-z.
5
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.在伊布替尼治疗后复发的 CLL 患者中，有三分之一的患者 BTK 和 PLCG2 未发生突变。
Blood Adv. 2023 Jun 27;7(12):2794-2806. doi: 10.1182/bloodadvances.2022008821.
6
Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors.与对非共价BTK抑制剂耐药相关的获得性BTK突变。
Blood Adv. 2023 Oct 10;7(19):5698-5702. doi: 10.1182/bloodadvances.2022008955.
7
Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia.功能检测鉴定和分层慢性淋巴细胞白血病中 PI3K 抑制剂的反应。
Clin Cancer Res. 2022 Oct 14;28(20):4444-4455. doi: 10.1158/1078-0432.CCR-22-1221.
8
PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?PI3K 抑制剂在慢性淋巴细胞白血病中的应用：我们的路在何方？
Haematologica. 2023 Jan 1;108(1):9-21. doi: 10.3324/haematol.2022.281266.